What This Top Dividend Portfolio Is Holding Now: GlaxoSmithKline plc, Centrica PLC and Vodafone Group plc

GlaxoSmithKline plc (LON:GSK), Centrica PLC (LON:CNA) and Vodafone Group plc (LON:VOD) are the heavyweight holdings of Murray Income Trust plc (LON:MUT).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Murray Income Trust (LSE: MUT) announced its annual results last month. The board lifted the dividend by 3.4% to record 30 years of unbroken growth. At a current share price of 762p the trailing yield is 4%.

Picking great dividend shares has helped Murray Income outperform the FTSE All-Share Index over the past three, five and 10 years.

Let’s take a look at the trust’s current top three holdings: GlaxoSmithKline (LSE: GSK), Centrica (LSE: CNA) and Vodafone (LSE: VOD) (NASDAQ: VOD.US).

GlaxoSmithKline

GlaxoSmithKline (GSK) is a longstanding favourite of income investors. The UK’s top pharmaceuticals group has continued to increase its dividend despite the recent years of patent expiries and threat from generic rivals.

Free cash flow has been tight of late but GSK has a strong late-stage pipeline of new treatments, and recent agreements to sell non-core drinks brands Lucozade and Ribena, and thrombosis brands Arixtra and Fraxiparine, will bring in handy cash of £2bn.

Analysts are forecasting a 4.2% increase in the dividend for the current year, giving a 5% yield at a recent share price of 1,540p.

Centrica

Shares of Centrica, the owner of British Gas, have come under the cosh recently as a result of Ed Miliband’s proposal to break up the ‘Big Six’ utilities and cap energy bills. High-profile fund manager Neil Woodford — Centrica’s largest shareholder — has slammed the proposal as “economic vandalism”.

Now could be a good time to invest in Centrica, if you believe Labour’s proposal is unworkable on the basis that, as Woodford says: “If Centrica and SSE cannot make any money supplying electricity to the retail market then they won’t supply it. The lights will go off …”

Centrica has been a reliable dividend payer, and the recent drop in the share price has pushed up the yield. With the shares trading at 368p, and analysts forecasting a 6% rise in this year’s dividend, the prospective income is 4.7%.

Vodafone

There was big news last month with the coming to fruition of Vodafone’s long-mooted sale of its 45% interest in US company Verizon Wireless to Verizon Communications.

On announcing the sale — worth a whopping $130bn — Vodafone said “The Board …  intends to increase the total 2014 financial year dividend per share by 8% to 11p”. At a recent share price of 217p that represents a yield of 5.1%.

Such an event as the game-changing sale of Verizon Wireless inevitably leads to some uncertainty. However, as far as the dividend is concerned, Vodafone has said that after the upcoming 11p a share payout, the board “intends to grow [the dividend] annually thereafter”.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline and Vodafone.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »